MedTrace Logo

Incidence of Hemocompatibility Events With or Without Aspirin in Patients With CH-VAD

NCT07343102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2026-01-15

No results posted yet for this study

Summary

The goal of this observational study is to investigate the impact of oral warfarin anticoagulation combined with or without aspirin on the incidence of non-surgical hemocompatibility-related adverse events (HRAEs) and survival in advanced heart failure patients after implantation of the fully magnetic levitation left ventricular assist device (CH-VAD).

The main question it aims to answer is : The incidence of non-surgical HRAEs and survival treated with oral warfarin anticoagulation combined with or without aspirin in Chinese CH-VAD implanted advanced heart failure patients.

CH-VAD has been approved in China for the treatment of patients with advanced heart failure.

Conditions

  • Hemocompatibility-related Adverse Event

Interventions

DEVICE

CH-VAD

Patients who underwent CH-VAD implantation.

Sponsors & Collaborators

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Sichuan Provincial People's Hospital

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Jiangsu Provincial People's Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Henan Provincial Chest Hospital

    collaborator OTHER

  • Wuhan Asia Heart Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Second Hospital of Jilin University

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2025-11-20
Completion
2025-11-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07343102 on ClinicalTrials.gov